- Investigational use not yet approved by regulators.
- Builds on LATITUDE study which showed superiority in virologically suppressed patients with adherence challenges.
- ViiV Healthcare (majority owned by GSK) announced that the phase IIIb CROWN study met its primary endpoint. At six months, long-acting Cabenuva (cabotegravir + rilpivirine, administered six times a year) achieved superior rates of viral suppression compared to standard-of-care daily oral antiretroviral therapy in adults and adolescents living with HIV-1 who had detectable virus at study entry and no resistance to INSTIs or NNRTIs.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card